Aclaris Therapeutics (ACRS)
NASDAQ:ACRS
Want to see ACRS full AI Analyst Report?
ACRS Stock Chart & Stats
$4.25
-$0.03(-1.20%)
At close: 4:00 PM EST
$4.25
-$0.03(-1.20%)
Day’s Range― - ―
52-Week Range$1.34 - $5.15
Previous CloseN/A
Volume227.82K
Average Volume (3M)1.11M
Market Cap
$646.64M
Enterprise Value$522.03M
Total Cash (Recent Filing)$105.42M
Total Debt (Recent Filing)$1.99M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Aug 12, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding139,663,680
10 Day Avg. Volume1,094,755
30 Day Avg. Volume1,106,653
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)3.58
Price to Sales (P/S)47.18
P/FCF Ratio-7.84
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue62.39
Enterprise Value/Gross Profit81.73
Enterprise Value/Ebitda-7.14
Forecast
1Y Price Target
$10.67Price Target Upside150.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.65
Revenue Forecast (FY)$5.71M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained high gross margins signal favorable unit economics for Aclaris’s biologics pipeline. If a candidate reaches commercialization, these margins support pricing power and faster path to operating leverage, meaning less revenue is required to move toward durable profitability.
Low Leverage / Minimal DebtVery low debt reduces solvency risk and preserves financial flexibility for R&D and clinical programs. Minimal leverage makes it easier to pursue partnerships or opportunistic financing without immediate liquidity stress, supporting program continuity over the next several quarters.
Positive Phase 1a ATI-052 Data And Focused Lead ChoicePositive first-in-human data for ATI-052, including a potentially infrequent dosing profile, plus a clear lead indication for ATI-2138 materially de-risks the pipeline. These structural clinical advances enhance partnership and licensing prospects and strengthen the company’s strategic development focus.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow (~-$52M TTM) forces dependence on external financing to sustain operations and trials. This ongoing burn constrains runway, pressures prioritization of programs, and makes long-term planning contingent on successful capital raises or partnerships.
Small, Volatile Revenue And Deep LossesAclaris lacks stable product revenue, leaving R&D and operations funded primarily by capital markets. Deep, persistent operating losses relative to revenue mean returns remain negative, limiting reinvestment capacity and increasing execution risk until a commercial asset is achieved.
Frequent Equity Raises; Dilution RiskRepeated equity financings underscore dependence on public markets to fund activities, diluting existing shareholders and potentially pressuring per-share economics. Ongoing access to capital is helpful but creates long-term dilution risk and signals that internal cash generation is insufficient.
Aclaris Therapeutics News
ACRS FAQ
What was Aclaris Therapeutics’s price range in the past 12 months?
Aclaris Therapeutics lowest stock price was $1.34 and its highest was $5.15 in the past 12 months.
What is Aclaris Therapeutics’s market cap?
Aclaris Therapeutics’s market cap is $646.64M.
When is Aclaris Therapeutics’s upcoming earnings report date?
Aclaris Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 69 days.
How were Aclaris Therapeutics’s earnings last quarter?
Aclaris Therapeutics released its earnings results on May 12, 2026. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.158 by $0.008.
Is Aclaris Therapeutics overvalued?
According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued.
Does Aclaris Therapeutics pay dividends?
Aclaris Therapeutics does not currently pay dividends.
What is Aclaris Therapeutics’s EPS estimate?
Aclaris Therapeutics’s EPS estimate is -0.16.
How many shares outstanding does Aclaris Therapeutics have?
Aclaris Therapeutics has 139,663,680 shares outstanding.
What happened to Aclaris Therapeutics’s price movement after its last earnings report?
Aclaris Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.158. Following the earnings report the stock price went down -1.414%.
Which hedge fund is a major shareholder of Aclaris Therapeutics?
Currently, no hedge funds are holding shares in ACRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aclaris Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.67 (150.98% Upside)
$10.67 (150.98% Upside)
Hedge Fund Trend
Increased
By 7.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.39%
12-Months-Change
Fundamentals
Return on Equity
-55.89%
Trailing 12-Months
Asset Growth
0.32%
Trailing 12-Months
Company Description
Aclaris Therapeutics
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
ACRS Stock 12 Month Forecast
Average Price Target
$10.67
▲(150.98% Upside)
Technical Analysis
Ownership Overview
12.34% Insiders
7.41% Mutual Funds
48.90% Other Institutional Investors
20.78% Public Companies and
Individual Investors